Literature DB >> 21402071

Translational application of epigenetic alterations: ovarian cancer as a model.

Marie E Maradeo1, Paul Cairns.   

Abstract

Cancer is a disease initiated and driven by the accumulation and interplay of genetic and epigenetic mutations of genes involved in the regulation of cell growth and signaling. Dysregulation of these genes and pathways in a cell leads to a growth advantage and clonal expansion. The epigenetic alterations involved in the initiation and progression of cancer are DNA methylation and histone modifications which interact to remodel chromatin, as well as RNA interference. These alterations can be used as candidate targets in molecular tests for risk, early detection, prognosis, prediction of response to therapy, and monitoring, as well as new therapeutic targets in cancer. In this review, we discuss the rationale, studies to date, and issues in the translational application of epigenetics using epithelial ovarian cancer as a specific example of all types of cancer.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402071      PMCID: PMC3129436          DOI: 10.1016/j.febslet.2011.03.016

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  128 in total

Review 1.  Emerging molecular markers of cancer.

Authors:  David Sidransky
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

2.  Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice.

Authors:  Cindy A Eads; Andrea E Nickel; Peter W Laird
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

3.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

4.  Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.

Authors:  L L McCluskey; C Chen; E Delgadillo; J C Felix; L I Muderspach; L Dubeau
Journal:  Gynecol Oncol       Date:  1999-01       Impact factor: 5.482

5.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.

Authors:  Susan H Wei; Chuan-Mu Chen; Gordon Strathdee; Jaturon Harnsomburana; Chi-Ren Shyu; Farahnaz Rahmatpanah; Huidong Shi; Shu-Wing Ng; Pearlly S Yan; Kenneth P Nephew; Robert Brown; Tim Hui-Ming Huang
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

6.  Suppression of intestinal neoplasia by DNA hypomethylation.

Authors:  P W Laird; L Jackson-Grusby; A Fazeli; S L Dickinson; W E Jung; E Li; R A Weinberg; R Jaenisch
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

7.  Methylation profiling of CpG islands in human breast cancer cells.

Authors:  T H Huang; M R Perry; D E Laux
Journal:  Hum Mol Genet       Date:  1999-03       Impact factor: 6.150

Review 8.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

9.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.

Authors:  A Catteau; W H Harris; C F Xu; E Solomon
Journal:  Oncogene       Date:  1999-03-18       Impact factor: 9.867

10.  Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers.

Authors:  N Collins; R Wooster; M R Stratton
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  13 in total

Review 1.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

3.  Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.

Authors:  Sabrina L Samudio-Ruiz; Laurie G Hudson
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

Review 4.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

Review 6.  Ovarian cancer: in search of better marker systems based on DNA repair defects.

Authors:  Dominic Varga; Miriam Deniz; Lukas Schwentner; Lisa Wiesmüller
Journal:  Int J Mol Sci       Date:  2013-01-04       Impact factor: 5.923

7.  Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.

Authors:  Anni Niskakoski; Sippy Kaur; Synnöve Staff; Laura Renkonen-Sinisalo; Heini Lassus; Heikki J Järvinen; Jukka-Pekka Mecklin; Ralf Bützow; Päivi Peltomäki
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

8.  Klotho promoter methylation status and its prognostic value in ovarian cancer.

Authors:  Maryam H Al-Zahrani; Fatimah M Yahya; Mourad Assidi; Ashraf Dallol; Abdelbaset Buhmeida
Journal:  Mol Clin Oncol       Date:  2021-07-03

9.  Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.

Authors:  Ilsiya Ibragimova; Marie E Maradeo; Essel Dulaimi; Paul Cairns
Journal:  Epigenetics       Date:  2013-05-01       Impact factor: 4.528

Review 10.  Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.

Authors:  Huimin Bai; Dongyan Cao; Jiaxin Yang; Menghui Li; Zhenyu Zhang; Keng Shen
Journal:  J Cell Mol Med       Date:  2016-01-22       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.